CONFERENCE COVERAGE SERIES
ACT-AD FDA/AD Allies Meeting, 2012
Rockville, Maryland, U.S.A.
29 November 2012
Combination Drug Trials: Time to Open a New Front in AD?
Over the past year, chatter has been building about combination drug therapy as the "New New Thing" in Alzheimer’s disease research...
Combination Trials: FDA Puts Flesh on Bones of Draft Guidance
Alzheimer's disease clinicians who have read the FDA's draft guidance on developing drug combinations consider it too vague to design trials with it...
Combination Trials: Companies Can Play Well in One Sandbox
In the AD field, most readers can count on one hand the companies that are widely known to have at least two drugs in sufficiently advanced stages to test combinations...
Building a Roadmap for Shared Combination Drug Trials
As potential AD drugs continue to post disappointing Phase 2/3 results, many in the field are considering upping the artillery by testing experimental drugs in combination.